CORRECTED: Novartis Knocks Colombia Over Leukemia Drug Price Control

Law360, New York (December 1, 2016, 7:22 PM EST) -- Swiss pharmaceutical giant Novartis has threatened to file an investor-state claim against Colombia over the country's decision to require a price control on Novartis' leukemia drug Glivec, a spokesman for the company confirmed on Thursday. 

The spokesman told Law360 that the company had filed its notice of dispute over certain intellectual property rights under a bilateral investment treaty between the South American nation and Switzerlan in April, several months before Colombia's Ministry of Health issued a decision in June to enforce a declaration of public interest requiring...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.